Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(Qt=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Ft)),notifLabel:document.querySelector(".".concat(Gt))};no(e,n)}))}()}};

NYSE American - Nasdaq Real Time Price • USD

0.9740 -0.0460 (-4.51%)

As of 3:58 PM EDT. Market Open.

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for LCTX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 1.0200
• Open 1.0300
• Bid 0.9800 x 800
• Ask 0.9810 x 1800
• Day's Range 0.9700 - 1.0600
• 52 Week Range 0.8400 - 1.6100
• Volume 1,037,523
• Avg. Volume 1,126,280
• Market Cap (intraday) 183.915M
• Beta (5Y Monthly) 1.39
• PE Ratio (TTM) --
• EPS (TTM) -0.1300
• Earnings Date Aug 8, 2024 - Aug 12, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 5.20

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

www.lineagecell.com

68

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Lineage Cell Therapeutics, Inc.

Recent News: LCTX

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

Lineage Cell Therapeutics Inc (LCTX) Stock Price & News - Google FinanceLineage Cell Therapeutics, Inc. (LCTX) Stock Price, Quote & News - Stock AnalysisLineage Cell Therapeutics Inc (LCTX) Stock Price & News - Google Finance

View More

Performance Overview: LCTX

Trailing total returns as of 6/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LCTX

10.64%

S&P 500

10.93%

1-Year Return

LCTX

26.21%

S&P 500

23.56%

3-Year Return

LCTX

64.96%

S&P 500

26.20%

5-Year Return

LCTX

1.62%

S&P 500

92.80%

Compare To: LCTX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

LCTXLineage Cell Therapeutics, Inc.

0.9740

-4.51%

Mkt Cap 183.915M

Industry Biotechnology

SERSerina Therapeutics, Inc.

9.58

-1.85%

Mkt Cap 80.563M

Industry Biotechnology

GERNGeron Corporation

3.9850

+4.05%

Mkt Cap 2.364B

Industry Biotechnology

KZRKezar Life Sciences, Inc.

0.6960

-1.78%

Mkt Cap 50.67M

Industry Biotechnology

ENLVEnlivex Therapeutics Ltd.

1.4100

-4.26%

Mkt Cap 29.429M

Industry Biotechnology

MAIAMAIA Biotechnology, Inc.

3.7550

-26.37%

Mkt Cap 81.999M

Industry Biotechnology

LPTXLeap Therapeutics, Inc.

2.3500

-5.24%

Mkt Cap 89.922M

Industry Biotechnology

RIGLRigel Pharmaceuticals, Inc.

0.9622

-2.13%

Mkt Cap 168.776M

Industry Biotechnology

MLECMoolec Science SA

1.1850

-1.25%

Mkt Cap 44.513M

Industry Biotechnology

HOOKHOOKIPA Pharma Inc.

0.7930

-8.75%

Mkt Cap 78.467M

Industry Biotechnology

BCLIBrainstorm Cell Therapeutics Inc.

0.4300

-14.00%

Mkt Cap 30.135M

Industry Biotechnology

Statistics: LCTX

View More

Valuation Measures

As of 6/3/2024

• Market Cap

  192.60M

• Enterprise Value

  152.23M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  22.41

• Price/Book (mrq)

  2.66

• Enterprise Value/Revenue

  19.02

• Enterprise Value/EBITDA

  --

Financial Highlights

Profitability and Income Statement

• Profit Margin

  -295.59%

• Return on Assets (ttm)

  -11.97%

• Return on Equity (ttm)

  -33.76%

• Revenue (ttm)

  8M

• Net Income Avi to Common (ttm)

  -23.66M

• Diluted EPS (ttm)

  -0.1300

Balance Sheet and Cash Flow

• Total Cash (mrq)

  43.62M

• Total Debt/Equity (mrq)

  4.58%

• Levered Free Cash Flow (ttm)

  -8.05M

View More

Research Analysis: LCTX

View More

View More

People Also Watch

OCX OncoCyte Corporation

2.6485

-1.91%

LPTX Leap Therapeutics, Inc.

2.3500

-5.24%

CLSD Clearside Biomedical, Inc.

1.2500

-3.09%

VTGN Vistagen Therapeutics, Inc.

3.9450

+0.38%

XERS Xeris Biopharma Holdings, Inc.

2.3250

-5.10%

SYBX Synlogic, Inc.

1.5700

-4.85%

MTNB Matinas BioPharma Holdings, Inc.

0.1550

-2.76%

OTLK Outlook Therapeutics, Inc.

7.21

+3.00%

PDSB PDS Biotechnology Corporation

2.9000

-0.17%

ALRN Aileron Therapeutics, Inc.

3.2351

+1.10%

KZR Kezar Life Sciences, Inc.

0.6960

-1.78%

MREO Mereo BioPharma Group plc

3.3250

-3.48%

ALDX Aldeyra Therapeutics, Inc.

4.0950

+6.63%

CKPT Checkpoint Therapeutics, Inc.

1.8700

+1.08%

PGEN Precigen, Inc.

1.6450

+5.45%

MBIO Mustang Bio, Inc.

0.1857

+3.69%